NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC Min/+) mice

Biochemical and Biophysical Research Communications

Volumn 313, Issue 3, 2004, Pages 784-788

  Williams, Jennie L ^a   Kashfi, Khosrow ^b   Ouyang, Nengtai ^a   Del Soldato, Piero ^c   Kopelovich, Levy ^d   Rigas, Basil ^a,c  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aspirin; Chemoprevention; Colon cancer; Min mice; Nitric oxide; Nitric oxide releasing aspirin; Proliferation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; CYCLINE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FEMALE; GASTROINTESTINAL TOXICITY; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE SECTION; WILD TYPE;

EID: 0346433820     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.12.015     Document Type: Article

References (16)

1. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94:2002;252-266.
2. Rayyan Y., Williams J., Rigas B. The role of NSAIDs in the prevention of colon cancer. Cancer Invest. 20:2002;1002-1011.
3. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., Snover D.C., Church T.R., Allen J.I., Beach M., Beck G.J., Bond J.H., Byers T., Greenberg E.R., Mandel J.S., Marcon N., Mott L.A., Pearson L., Saibil F., vanStolk R.U. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348:2003;891-899.
4. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J.M., Karp D.D., Loprinzi C.L., Steinback G., Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348:2003;883-890.
5. Rigas B., Williams J.L. NO releasing NSAIDs and colon cancer chemoprevention: a promising novel approach (Review). Int. J. Oncol. 20:2002;885-890.
6. Williams J.L., Borgo S., Hasan I., Castillo E., Traganos F., Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer chemoprevention. Cancer Res. 61:2001;3285-3289.
7. Fiorucci S., Santucci L., Gresele P., Faccino R.M., DelSoldato P., Morelli A. A Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology. 124:2003;600-607.
8. Lipkin M., Yang K., Edelmann W., Xue L., Fan K., Risio M., Newmark H., Kucherlapati R. Preclinical mouse models for cancer chemoprevention studies. Ann. N.Y. Acad. Sci. 889:1999;14-19.
9. Shiff S.J., Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology. 113:1997;1992-1998.
10. Kashfi K., Ryyan Y., Qiao L.L., Williams J.L., Chen J., Del Soldato P., Traganos F., Rigas B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther. 303:2002;1273-1282.
11. Bak A.W., McKnight W., Li P., Del Soldato P., Calignano A., Cirino G., Wallace J.L. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci. 62:1998;367-373.
12. C.V. Rao, B. Simi, I. Cooma, B. Rigas, L. Kopelovich, B.S. Reddy, Chemoprevention of colonic aberrant crypt foci by nitric oxide (NO) releasing NSAIDs. Abstract (2002), Proceedings of Frontiers in Cancer Prevention Research Boston, MA.
13. Jacoby R.F., Seibert K., Cole C.E., Kelloff G., Lubert R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in min mouse model of adenomatous polyposis. Cancer Res. 60:2002;5040-5044.
14. Yang K., Fan K., Kurihara N., Shinozaki H., Rigas B., Augenlicht L., Kopelovich L., Edelmann W., Kucherlapati R., Lipkin M. Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis. 24:2003;605-611.
15. Nath N., Kashfi K., Chen J., Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (tcf) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc. Natl. Acad. Sci. USA. 100:2003;12584-12589.
16. Williams J.L., Nath N., Chen J., Hundley T.R., Gao J., Kopelovich L., Kashfi K., Rigas B. Growth inhibition of human colon cancer cells by NO-donating aspirin is associated with COX-2 induction and beta-catenin/TCF signaling, NF-kappaB and NOS2 inhibition: implications for chemoprevention. Cancer Res. 63:2003;7613-7618.